Note we may have some server downtime today and this weekend as we perform some upgrades. Please save a copy of any posts you make during this time in case we have any server trouble. Thank you!

Risk stratification for PML in patients treated with Tysabri

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Risk stratification for PML in patients treated with Tysabri

Postby MSUK » Mon Feb 13, 2012 3:15 am



Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).

Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).

We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - ... ageid/1768
User avatar
Family Elder
Posts: 2109
Joined: Wed Oct 14, 2009 3:00 pm

Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service